Product logins

Find logins to all Clarivate products below.


DRG Epidemiology’s coverage of osteoarthritis (OA) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of OA in each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.

DRG Epidemiology’s OA forecast will answer the following questions:

  • How will changes in the levels of exposure to known risk or protective factors affect the number of people living with a diagnosis of OA?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of OA over the forecast period?

All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

DRG Epidemiology forecasts one OA patient population:

  • Diagnosed prevalent cases.

Note: Coverage may vary by country.

Related Market Assessment Reports

Report
Rheumatoid Arthritis – Unmet Need – Unmet Need – TNFi-Refractory Rheumatoid Arthritis (US/EU)
Rheumatoid arthritis (RA) patients who are refractory to one or more tumor necrosis factor (TNF)-alpha inhibitors are generally prescribed a non-TNF-targeted therapy (e.g., Bristol Myers Squibb’s…
Report
Psoriatic Arthritis – Landscape & Forecast – Disease Landscape & Forecast (G7)
The psoriatic arthritis (PsA) treatment market is experiencing significant shifts with the introduction of newer targeted therapies, such as AbbVie’s Rinvoq and Skyrizi, and UCB’s bimekizumab…
Report
Axial Spondyloarthritis – Unmet Need – Unmet Need – Ankylosing Spondylitis (US/EU)
Over the past two decades, TNF-α inhibitors (AbbVie’s Humira, Amgen / Pfizer’s Enbrel, Johnson & Johnson Innovative Medicine’s Remicade and Simponi, and UCB’s Cimzia) have significantly…
Report
Hypertension – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of hypertension includes epidemiological estimates for key patient populations across 45 countries worldwide. We report the prevalence of hypertension for each…
Report
Endometrial Cancer – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of endometrial cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…